1. Home
  2. |Insights
  3. |Consortium Awarded $30 Million for Manufacturing Pilot Program

Consortium Awarded $30 Million for Manufacturing Pilot Program

Client Alert | 1 min read | 08.23.12

On August 16, the Obama administration announced both a $30 million award  that may serve as a model for future partnerships geared towards manufacturing innovation to the National Additive Manufacturing Innovation Institute (NAMII) and a "pilot" program for the Administration's National Network of Manufacturing Innovation plan to invest $1 billion "to catalyze a national network of up to 15 manufacturing innovation institutes around the country." NAMII, which was selected in response to a Broad Agency Announcement solicitation, is a consortium including dozens of major government contractors and manufacturing firms, universities, and non-profit organizations which will "co-invest" $40 million to develop additive manufacturing technology (a process by which products and components are manufactured more efficiently using digital models).

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights